TABLE 5.
Antibacterial efficacy in a murine acute lethal infection model
| Infecting organism | PD50a ± 95% confidence limit (mg/kg) (MIC [μg/ml])
|
||
|---|---|---|---|
| PD 0305970 | Ciprofloxacin | Levofloxacin | |
| S. aureus UC-76 (MSSAb) | 1.9 ± 0.7 (0.06) | 9.1 ± 2.2 (0.06) | 4.6 ± 1.2 (0.125) |
| S. aureus SA-1417 (MRSA) | 2.5 ± 1.8 (0.25) | 18.0 ± 6.9 (0.5) | Not tested (0.25) |
| S. aureus SA-2017 (CMRSAc) | 23 ± 5.2 (0.25) | >100 (>64) | Not tested (8) |
| Streptococcus pneumoniae SVI | 2.7 ± 0.8 (0.015) | >100 (2) | 69 ± 37 (0.5) |
| S. pyogenes C203d | 0.7 ± 0.1 (0.015) | >100 (0.5) | 17.7 ± 2.1 (0.5) |
| Enterococcus faecalis MGH-2 | 19 ± 6.1 (0.125) | Not tested (0.5) | Not tested (1) |
| Escherichia coli Vogel | 82 ± 31 (1) | Not tested (0.03) | Not tested (0.06) |
a
Oral drug dose protecting 50% of mice challenged with 100 50% lethal doses from a lethal bacterial infection.
b
MSSA, methicillin-susceptible Staphylococcus aureus.
c
CMRSA, ciprofloxacin- and methicillin-resistant Staphylococcus aureus.
d
PD 0326448 PD50 = 3.6 mg/kg (MIC = 0.015 μg/ml).